Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-10-25
2005-10-25
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S212050, C514S212060, C514S212070, C514S212080, C540S519000, C540S520000, C540S521000, C540S522000, C540S523000
Reexamination Certificate
active
06958330
ABSTRACT:
Disclosed are polycyclic α-amino-ε-caprolactams and related compounds which are useful as synthetic intermediates in the preparation of inhibitors of β-amyloid peptide release and/or its synthesis.
REFERENCES:
patent: 2938029 (1960-05-01), Brenner et al.
patent: 3598859 (1971-08-01), Yates et al.
patent: 3657341 (1972-04-01), Thorne
patent: 4080449 (1978-03-01), Croisier et al.
patent: 4460579 (1984-07-01), Karanewsky
patent: 4477464 (1984-10-01), Slade et al.
patent: 4666829 (1987-05-01), Glenner et al.
patent: 4977168 (1990-12-01), Bernat et al.
patent: 5238932 (1993-08-01), Flynn et al.
patent: 5283241 (1994-02-01), Bochis et al.
patent: 5284841 (1994-02-01), Chu et al.
patent: 5324726 (1994-06-01), Bock et al.
patent: 5360802 (1994-11-01), Chambers et al.
patent: 5420271 (1995-05-01), Warshawsky et al.
patent: 5478857 (1995-12-01), Clemens et al.
patent: 5556969 (1996-09-01), Chambers et al.
patent: 5618792 (1997-04-01), Gyorkos et al.
patent: 5633251 (1997-05-01), Claremon et al.
patent: 5644055 (1997-07-01), De Lombaert
patent: 5658901 (1997-08-01), Claremon et al.
patent: 5712397 (1998-01-01), Esser et al.
patent: 5770573 (1998-06-01), Arrhenius et al.
patent: 5968927 (1999-10-01), Karanewsky et al.
patent: 6200969 (2001-03-01), Fritz et al.
patent: 0 061 187 (1982-09-01), None
patent: 0 167 919 (1986-01-01), None
patent: 0 284 256 (1988-09-01), None
patent: 0 349 949 (1990-01-01), None
patent: 0 376 849 (1990-07-01), None
patent: 0 434 360 (1991-06-01), None
patent: 0 434 364 (1991-06-01), None
patent: 0 434 369 (1991-06-01), None
patent: 0 490 590 (1992-06-01), None
patent: 0 514 133 (1992-11-01), None
patent: 0 523 845 (1993-01-01), None
patent: 0 549 039 (1993-06-01), None
patent: 0591529 (1994-04-01), None
patent: 0 647 632 (1995-04-01), None
patent: 0647632 (1995-04-01), None
patent: 0 652 009 (1995-08-01), None
patent: 0 667 344 (1995-08-01), None
patent: 0 677 517 (1995-10-01), None
patent: 0 732 399 (1996-09-01), None
patent: 810221 (1997-03-01), None
patent: 0 778 266 (1997-11-01), None
patent: 0945445 (1999-09-01), None
patent: 1 519 495 (1978-07-01), None
patent: 1519495 (1978-07-01), None
patent: 1 573 931 (1980-08-01), None
patent: 2 272 439 (1994-05-01), None
patent: 2 290 788 (1996-01-01), None
patent: 71515 (1995-12-01), None
patent: 5247033 (1993-09-01), None
patent: 06145148 (1994-05-01), None
patent: 04210967 (1994-08-01), None
patent: 6211812 (1994-08-01), None
patent: 07304770 (1995-11-01), None
patent: 10072444 (1998-03-01), None
patent: 179757 (1998-04-01), None
patent: 10101560 (1998-04-01), None
patent: 92/01683 (1992-02-01), None
patent: WO 92/11246 (1992-07-01), None
patent: WO 92/16524 (1992-10-01), None
patent: 92/16524 (1992-10-01), None
patent: 93/19052 (1993-09-01), None
patent: 93/19063 (1993-09-01), None
patent: WO 94/00438 (1994-01-01), None
patent: 94/04531 (1994-03-01), None
patent: 94/05693 (1994-03-01), None
patent: 94/07486 (1994-04-01), None
patent: 94/10569 (1994-05-01), None
patent: WO 94/25445 (1994-11-01), None
patent: WO 95/03285 (1995-02-01), None
patent: 95/03289 (1995-02-01), None
patent: 95/03290 (1995-02-01), None
patent: 95/09838 (1995-04-01), None
patent: 95/14671 (1995-06-01), None
patent: 95/21840 (1995-08-01), None
patent: 95/23810 (1995-09-01), None
patent: WO 95/25117 (1995-09-01), None
patent: 95/25118 (1995-09-01), None
patent: 95/32191 (1995-11-01), None
patent: 96/05839 (1996-02-01), None
patent: 96/16981 (1996-06-01), None
patent: 96/20725 (1996-07-01), None
patent: 96/22966 (1996-08-01), None
patent: WO 96/25408 (1996-08-01), None
patent: WO 96/29313 (1996-09-01), None
patent: 96/40146 (1996-12-01), None
patent: 96/40653 (1996-12-01), None
patent: 96/40654 (1996-12-01), None
patent: 96/40655 (1996-12-01), None
patent: 96/40656 (1996-12-01), None
patent: WO 97/16410 (1997-05-01), None
patent: 97/30072 (1997-08-01), None
patent: 97/38705 (1997-10-01), None
patent: WO 97/38705 (1997-10-01), None
patent: 98/00405 (1998-01-01), None
patent: WO 98/04539 (1998-02-01), None
patent: WO 98/22430 (1998-05-01), None
patent: WO 98/22433 (1998-05-01), None
patent: WO 98/22494 (1998-05-01), None
patent: WO 98/25911 (1998-06-01), None
patent: 98/25930 (1998-06-01), None
patent: 98/28268 (1998-07-01), None
patent: WO 98/38177 (1998-09-01), None
patent: 98/38177 (1998-09-01), None
Aquino, et al. Discovery of 1.5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonist Activity. 1. Optimization of the Agonist “Trigger.”J. Med. Chem.39: 562-569 (1996).
Bock, et al. “Selective Non-Peptide Ligands for an Accommodating Peptide Receptor. Imidazobenzodiazepines as Potent Cholecystokinin Type B Receptor Antagonists.”Bioorg. and Med. Chem. Lets.2(9):987-998 (1994.
Bock, et al. “Synthesis and Resolution of 3-Amino-1, 3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones.”J. Org. Chem.52:3232-3239 (1987).
Bock, et al. “An Expedient Synthesis of 3-Amino-1,3-Dihydro-5-Phenyl-2H-1,4-Benzodiazepin-2-one.”Tet. Lets.28(9): 939-942 (1987).
Chambers, et al. L-708,474: the C5-Cyclohexyl Analogue of L-365,260, A Selective High Affinity Ligand for the CCKB/Gastrin Receptor.Bioorg. and Med. Chem. Letts.3(10):1919-1924 (1993).
Chartier-Harlin, et al. “Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-Amyloid precursor protein gene.”Nature.353: 844-846 (1991).
Citron, et al. “Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-amyloid protein production.”Nature360:672-674 (1992).
Cordell. “B-Amyloid Formation as a Potential Therapeutic Target for Alzheimer's Disease.”Ann. Rev. Pharmacol. Toxicol.34:69-89 (1994).
Evans, et al. “Methods for Drug Discovery: Development of Potent, Selective Orally Effective Cholecystokinin Antagonists,”J. Med. Chem.31:2235-2246 (1988).
Evans, et al. “Molecular Mimicry and the Design of Pepidomimetrics.”Molecular Mimicry in Health and Disease.(A. Lernmark, et al., eds.) Elsevier Science Publishers B.v. (Biomedical Division) (1988) pp. 23-24.
Finizia, et al. “Synthesis and Evaluation of Novel 1,5-Benzodiazepines as potent and selective CCK-B Ligands, Effect of the Substitution of the N-5 Phenyl with Alkyl Groups.”Bioorg. &Medicinal Chemistry Letters.6(24):2957-2962 (1996).
Glenner, et al. “Alzheimer's disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein.”Biochem. Biophys. Res. Commun.120(3): 885-890 (1984).
Goate, et al. “Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease.”Nature.349: 704-706 (1991).
Hirst, et al. “Discovery of 1,5-Benzodiazepines with Peripheral Cholecystokinin (CCK-A) Receptor Agonists Activity (II): Optimization of the C3 Amino Substituent.”J. Med. Chem.39: 5236-5245 (1996).
Hofmann, et al. “Interactions of Benzodiazepine Derivatives with Annexins.”J. Biol. Chem.273(5):2885-2894 (1998).
Johnson-Wood, et al. “Amyloid precursor protein processing and Aβ42deposition in a transgenic mouse model of Alzheimer's disease.”PNAS USA.94: 1550-1555 (1997).
Ksander, G.M., et al. “Dual Angiotensin Converting Enzyme/Thromboxane Synthase Inhibitors.”J. Med. Chem.37: 1823-1832 (1994).
Lowe, et al. “A Water Soluble Benzazepine Cholecystokinin-B-Receptor Antagonist.”Bioorg. and Med. Chem. Lets.5(17): 1933-1936 (1995).
Lowe, et al. “5-Phenyl-3-ureidobenzzazepin-2-ones as Cholecystokinin-B Receptor Antagonists.”J. Med. Chem.37: 3789-3811 (1994).
Mullan, et al. “A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of β-amyloid.”Nature Genet.1: 345-347 (1992).
Murrell, et al. “A Mutation in the Amyloid Precursor Protein Associate with Hereditary Alzheimer's Disease.”Science.254: 97-99 (1991).
Papadopoulos, et al. Anodic Oxidation of N-Acyl and N-Alkoxylcarbonyl Dipeptide Esters as a K
Audia James E.
Mabry Thomas E.
McDaniel Stacey L.
Nissen Jeffrey A.
Porter Warren J.
Burns Doane Swecker & Mathis L.L.P.
Elan Pharmaceuticals Inc.
Eli Lilly and Company
Kifle Bruck
LandOfFree
Polycyclic α-amino-ε-caprolactams and related... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polycyclic α-amino-ε-caprolactams and related..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polycyclic α-amino-ε-caprolactams and related... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3449704